000089864 001__ 89864
000089864 005__ 20240104111816.0
000089864 0247_ $$2doi$$a10.3390/toxins12050330
000089864 0248_ $$2sideral$$a118090
000089864 037__ $$aART-2020-118090
000089864 041__ $$aeng
000089864 100__ $$0(orcid)0000-0001-5193-7782$$aMoreno-Martinez, L.$$uUniversidad de Zaragoza
000089864 245__ $$aNeuroprotective Fragment C of Tetanus Toxin Modulates IL-6 in an ALS Mouse Model
000089864 260__ $$c2020
000089864 5060_ $$aAccess copy available to the general public$$fUnrestricted
000089864 5203_ $$aNeuroinflammation plays a significant role in amyotrophic lateral sclerosis (ALS) pathology, leading to the development of therapies targeting inflammation in recent years. Our group has studied the tetanus toxin C-terminal fragment (TTC) as a therapeutic molecule, showing neuroprotective properties in the SOD1G93A mouse model. However, it is unknown whether TTC could have some effect on inflammation. The objective of this study was to assess the effect of TTC on the regulation of inflammatory mediators to elucidate its potential role in modulating inflammation occurring in ALS. After TTC treatment in SOD1G93A mice, levels of eotaxin-1, interleukin (IL)-2, IL-6 and macrophage inflammatory protein (MIP)-1 alpha (a) and galectin-1 were analyzed by immunoassays in plasma samples, whilst protein expression of caspase-1, IL-1ß, IL-6 and NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) was measured in the spinal cord, extensor digitorum longus (EDL) muscle and soleus (SOL) muscle. The results showed reduced levels of IL-6 in spinal cord, EDL and SOL in treated SOD1G93A mice. In addition, TTC showed a different role in the modulation of NLRP3 and caspase-1 depending on the tissue analyzed. In conclusion, our results suggest that TTC could have a potential anti-inflammatory effect by reducing IL-6 levels in tissues drastically affected by the disease. However, further research is needed to study more in depth the anti-inflammatory effect of TTC in ALS.
000089864 536__ $$9info:eu-repo/grantAgreement/ES/DGA/FSE$$9info:eu-repo/grantAgreement/ES/FEDER/Una manera de hacer Europa$$9info:eu-repo/grantAgreement/ES/FIS/PI17-00949$$9info:eu-repo/grantAgreement/ES/UZ-DGA/Grupos Consolidados
000089864 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000089864 590__ $$a4.546$$b2020
000089864 591__ $$aTOXICOLOGY$$b21 / 93 = 0.226$$c2020$$dQ1$$eT1
000089864 591__ $$aFOOD SCIENCE & TECHNOLOGY$$b32 / 143 = 0.224$$c2020$$dQ1$$eT1
000089864 592__ $$a1.046$$b2020
000089864 593__ $$aToxicology$$c2020$$dQ1
000089864 593__ $$aHealth, Toxicology and Mutagenesis$$c2020$$dQ1
000089864 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000089864 700__ $$0(orcid)0000-0002-7955-7164$$ade la Torre, M.$$uUniversidad de Zaragoza
000089864 700__ $$0(orcid)0000-0001-8301-6902$$aMuñoz, M.J.$$uUniversidad de Zaragoza
000089864 700__ $$0(orcid)0000-0001-5740-0185$$aZaragoza, P.$$uUniversidad de Zaragoza
000089864 700__ $$aAguilera, J.
000089864 700__ $$0(orcid)0000-0002-7277-4318$$aCalvo, A.C.
000089864 700__ $$0(orcid)0000-0001-5687-6704$$aOsta, R.$$uUniversidad de Zaragoza
000089864 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000089864 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000089864 773__ $$g12, 5 (2020), 330 [10 pp]$$pToxins$$tToxins$$x2072-6651
000089864 8564_ $$s630854$$uhttps://zaguan.unizar.es/record/89864/files/texto_completo.pdf$$yVersión publicada
000089864 8564_ $$s500829$$uhttps://zaguan.unizar.es/record/89864/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000089864 909CO $$ooai:zaguan.unizar.es:89864$$particulos$$pdriver
000089864 951__ $$a2024-01-04-11:05:08
000089864 980__ $$aARTICLE